Basilea’s antibiotic trials (and tribulations) may resolve in Q4
This article was originally published in Scrip
Executive Summary
Basilea Pharmaceutica expects the results of a clinical data audit for its experimental antibiotic, ceftobiprole, to be available in the fourth quarter, which it will use to 'support discussions with health authorities' in pursuing the indications of hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP), the company said in announcing its first-half results for 2011.